冠状动脉旋磨术在高危钙化病变中应用的单中心经验

目的 总结冠状动脉旋磨术在高危冠状动脉钙化病变中应用的经验,分析该技术治疗高危钙化病变患者的安全性及近、远期预后.方法 回顾分析2010年1月至2014年12月接受冠状动脉旋磨术结合支架植入术治疗患者130例,其中符合高危复杂钙化病变患者23例.分析术前术后冠状动脉DSA造影资料及临床信息,评估介入术并发症和主要心脑血管不良事件发生率.结果 23例患者26处钙化病变均接受冠状动脉旋磨术,其中15处(57.7％)、7处(26.9％)、4处(15.4％)病变分别以初始直径1.25 mm、1.5 mm、1.75 mm磨头开始旋磨.23处病变(88.5％)成功旋磨并顺利植入支架,即刻效果满意,无并发症;3处(11.5％)病变未植入支架,原因分别为血管太细、血管穿孔和支架内再狭窄,仅作旋磨术.术中发生冠状动脉夹层1处(3.8％),支架植入后边支闭塞2处(7.7％),血管穿孔1处(3.8％),无复流2处(7.7％)及支架内残余狭窄1例(3.8％).住院期间无死亡事件发生,发生支架植入术后心肌梗死3例(13.0％),对比剂肾病2例(8.7％).术后1年随访发现5例(21.7％)心绞痛症状再发,其中2例经造影证实与支架内再狭窄有关.21例获随访4～60个月,平均(25.5±10.7)个月,结果4例病死,2例再行血管重建术.结论 冠状动脉旋磨术治疗高危钙化病变安全、有效,术中根据病变特点遵循“磨头更小、推进更慢、分段旋磨”的原则,手术成功率高,并发症发生率低,术后主要心脑血管不良事件发生率低.     

裸支架治疗症状性肠系膜上动脉夹层中长期疗效观察

目的中长期随访观察血管腔内裸支架植入术治疗症状性肠系膜上动脉夹层(SDSMA)的疗效。方法回顾性分析8例接受血管内支架植入术的SDSMA(Yun血管影像学分型方法:Ⅰ型3例,Ⅱa型4例,Ⅱb型1例)患者资料。8例患者均行肠系膜上动脉裸支架植入术,术后以抗凝或终身抗血小板治疗。术后6个月、1年、2年行CTA复查,显示支架内血流通畅,动脉夹层消失。结果 8例患者共植入自膨式裸支架11枚,其中单支架5例,双支架3例。术后造影显示肠系膜上动脉病变段假腔未显影或显影较淡,真腔血流通畅,手术成功率100%。8例患者术后平均随访32个月,期间均无腹痛、腹胀及消化道出血症状。结论血管腔内裸支架植入术治疗症状性肠系膜上动脉夹层安全、有效,中长期效果满意。     

高危急性冠脉综合征急诊介入治疗150例分析

目的　通过分析急诊经皮冠状动脉介入治疗 (PCI)对高危急性冠脉综合征 (ACS)的疗效 ,探讨急诊PCI对高危ACS的策略。方法　入选 2 0 0 1年 12月 7日至 2 0 0 4年 8月 2 2日来院的高危ACS(ST抬高的急性心肌梗死和非ST抬高的急性心肌梗死共 15 0例。发病时间在 2 4h内 ,从发病到来院时间 <6h ,6～ 12h和 12～ 2 4小时的比例分别为 6 0 %、2 5 %和 15 %。行急诊冠状动脉造影 (CAG)和急诊PCI,并随访观察。结果　 15 0例入选患者均行急诊冠脉造影 ,14 3例行急诊PCI,其中直接植入支架 6 0例 ,PTCA后植入支架 80例 ,仅行PTCA 3例。 4例延迟植入支架 ,3例早期病变。梗死相关血管 (IRA)前向血流达到TIMIⅢ级为 99.3%。单支病变 双支病变、3支病变和早期病变分别占 2 8% 4 6 % 2 4 %和 2 %。从来院到导管室时间平均 5 0min ,从进导管室到梗死血管开通时间平均 1h。术中发生慢血流2 1例 ,经冠脉内给药好转 ,无血流 1例 ,治疗无效 ,术后急性闭塞 2例 ,分别再次PCI和IABP治疗好转。IABP治疗 12例 ,1例无效。院内死亡 7例 ,其中术中无血流 1例 ,术中心源性休克 1例 ,术中室颤 1例 ,术后室颤 1例 ,术后顽固心衰 2例 ,术后心脏破裂 1例 ,病死率 4 .7%。 14 3例随访 ,随访时间为 30～ 993d ,出现心绞痛 3例 ,心力衰竭 3     

冠心病临床造影分型与冠脉支架疗效的对照研究

目的 :探讨冠心病临床及造影分型与冠脉内支架植入疗效的关系。方法 :分析 135例冠脉支架植入术。149支靶血管单纯型病变 36支 ,复杂型 113支。支架适应证 primary植入 15例 ,denovo30例 ,suboptimal 5 7例 ,bail- out33例。共植入支架 16 2只。结果 :稳定型心绞痛复杂型血管病变占 13.3% (2 /15 ) ,不稳定型心绞痛占 81% (4 7/5 8) ,心梗占 84% (6 3/75 ) ,前者与后两者有显著性差异 (P<0 .0 0 5 ) ,但手术近、远期疗效则无显著性差异 (P>0 .1)。术后残余狭窄平均为 3.2± 7.0 % ,无严重并发症。 14例冠脉造影随访 ,平均随访 90 .5 d,2例出现再狭窄 (14.3% )。结论 :冠心病稳定型心绞痛血管病变以单纯型为主 ,其它类型则以复杂型为主 ,支架植入均可收到同样满意的疗效     

西藏地区直接冠状动脉支架植入术17例临床分析

目的评估西藏地区直接冠状动脉支架植入术治疗冠心病患者的临床疗效。方法回顾性分析我院2006年9月～2009年10月应用直接支架植入术治疗的冠心病患者17例,其中单支血管病变8例,双支血管病变6例,三支血管病变3例。结果 17例病变血管29支,共植入支架27枚,成功率93.1%,术后冠状动脉造影证实狭窄消失,并随访半年以上效果良好。结论 在高原地区直接冠脉支架植入术仍是一种安全有效的心脏介入性治疗技术。     

急性心肌梗死支架植入后早期行3 T心脏MR成像的临床安全性

<正>研究的目的是前瞻性评估急性心肌梗死(AMI)病人冠状动脉裸金属或药物洗脱冠状动脉支架植入后早期(14d)行3T心脏MR(CMR)成像的安全性。连续72例接受经皮支架植入血运重建治疗的AMI病人在平均6d时行CMR检查。住院期间及6个月内随访观察有无主要心脏不良事件。CMR成像后6个月的随访期内     

经皮冠状动脉成形支架植入术后护理

经皮冠状动脉成形 (ＰＴＣＡ)并支架植入术是治疗冠状动脉狭窄和闭塞最有效的方法。具有手术简便、创伤少、疗效确切、安全可靠等优点[1,2 ] 。我院自 1998年 3月～ 2 0 0 1年 4月共施 31例冠状动脉支架植入术 ,均取得较好的疗效。现就其护理经验及体会总结如下。临床资料本组 31例 ,男 2 7例 ,女 4例 ,年龄 4 8～ 74岁。平均年龄 6 1岁。所有病例均经临床检查、心电图、彩超及冠状动脉造影确诊。 31例患者共植入支架4 2个 ,其中植入 1枚支架者 2 2例 ,2枚支架者 7例 ,3枚支架者 2例。 31例患者中 ,术后 2 0例出现不同程度的心律失常 ,3例出…     

髂动脉内支架植入术后临床及血管造影随访

目的　评价经皮腔内成形术 (PTA)及支架植入术治疗髂动脉的动脉硬化性狭窄的早期及晚期临床疗效。方法　从 1994年 12月～ 2 0 0 0年 2月 ,为 31名患者的 4 2条髂动脉血管内植入 4 4个Wallstent支架 ,进行临床及血管造影随访。结果　 4 4个支架植入操作均获成功。 1例患者回家后第 3天穿刺部位血肿 ,超声检查为假性动脉瘤 ,行外科手术修复 ,术后半年血管造影检查无再狭窄。临床随访 (36± 13)个月 ,术后间歇性跛行及休息痛等症状均消失。 31例患者中有 2 0例 (2 9条血管 )进行血管造影随访 ,随访时间 (10± 5 )个月。血管造影随访时有 1例患者的 1条髂动脉出现再狭窄 ,再狭窄率 2 %(1/ 4 2 ) ,成功地再次行PTA。结论　髂动脉PTA和支架术是一种安全有效的方法 ,成功率高 ,并发症少 ,再狭窄率低 ,可作为髂动脉狭窄的首选治疗方法。     

外周动脉狭窄-梗阻性病变的综合介入治疗

目的 :评价外周动脉狭窄 梗阻性病变的综合介入治疗疗效及在合并严重器质性心脏病患者的安全性和有效性。方法 :从 1987年 10月至 2 0 0 5年 2月 ,共有 173例患者 (2 0 3支病变血管 )接受了外周动脉综合介入治疗。男 ,116例 ,女 ,5 7例 ,年龄 2 .5岁～ 79岁 ,平均 4 4 .1岁。其中 37例合并冠心病 ,4例合并瓣膜性心脏病 ,5例合并先天性心脏病。行单纯溶栓术 2 0例 ,溶栓术 PTA术 5例 ,溶栓术 PTA 支架植入 3例 ,单纯PTA术 6 3例 ,PTA 支架植入术 6 8例 ,直接支架植入术 8例 ,单纯导管切削术 2例 ,切削 PTA术 1例 ,切削 溶栓 1例。结果 :总的技术成功率为 93.0 % (15 9 171例 ) ,主要并发症发生率为 7.1% (12 170例 ) ,病死率为 0。其中 ,颈动脉支架植入术 9例 ,技术成功率为 10 0 % ;锁骨下动脉PTA或 和支架植入术 2 3例 ,技术成功率为 95 .7% ;主动脉溶栓、成形术 (PTA)或 (和 )支架植入术 2 8例 ,技术成功率为 96 .4 % ;肾动...     

血管内支架成形术治疗高危颈动脉狭窄

目的　探讨血管内支架成形术治疗高危颈动脉狭窄的可行性和安全性。资料与方法　自 2 0 0 0年 12月～ 2 0 0 1年 6月 ,共采用血管内支架植入术治疗不宜行颈动脉内膜切除术 (CEA)的高危颈动脉狭窄患者 14例 ,其中 3例为无症状者。结果　所有患者均成功地植入支架。术前、术后平均狭窄程度分别为 (82 .3± 5 .1) %、(17.0± 3.8) %。1例术中发生同侧颞叶梗死但恢复良好 ,无其他手术并发症。临床随访 1年以上无 1例缺血再发作 ,影像学检查无再狭窄。结论　血管内支架成形术治疗颈动脉狭窄是安全有效的 ,特别适合于行CEA高危的患者     

Knee injury and Osteoarthritis Outcome Score (KOOS) - validation of a Swedish version

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a self-administered instrument measuring outcome after knee injury at impairment, disability, and handicap level in five subscales. Reliability, validity, and responsiveness of a Swedish version was assessed in 142 patients who underwent arthroscopy because of injury to the menisci, anterior cruciate ligament, or cartilage of the knee. The clinimetric properties were found to be good and comparable to the American version of the KOOS. Comparison to the Short Form-36 and the Lysholm knee scoring scale revealed expected correlations and construct validity. Item by item, symptoms and functional limitations were compared between diagnostic groups. High responsiveness was found three months after arthroscopic partial meniscectomy for all subscales but Activities of Daily Living.     

Endovascular management of carotid-cavernous fistulas

Objective To investigate endovascular treatment of traumatic direct carotid-cavernous fistulas （CCF） and their complications such as pseudoaneurysms. Methods： Over a five-year period, 22 patients with traumatic direct CCFs were treated endovascularly in our institution. Thirteen patients were treated once with the result of CCF occluded, 8 twice and 1 three times. Treatment modalities included balloon occlusion of the CCF, sacrifice of the ipsilateral internal carotid artery with detachable balloon, coll embolization of the cavernous sinus and secondary pseudoaneurysms, and covered-stem management of the pseudoaneurysms. Results All the direct CCFs were successfully managed endovascularly. Four patients developed a pseudoaneurysm after the occlusion of the CCF with an incidence of pseudoaneurysm formation of 18.2% （4/22）. A total number of 8 patients experienced permanent occlusion of the ICA with a rate of ICA occlusion reaching 36.4% （8/22）. Followed up through telephone consultation from 6 months to 5 years, all did well with no recurrence of CCF symptoms and signs. Conclusion Traumatic direct CCFs can be successfully managed with endovascular means. The pseudoaneurysms secondary to the occlusion of the CCFs can be occluded with stent-assisted coiling and implantation of covered stents.     

The acutely limping child

Acute limping may be the result of multiple pathologies in children. The differential diagnosis varies based on the age of the child. Irrespective of age, the initial imaging work-up includes AP and frog leg radiographs of the pelvis and ultrasound; MRI may sometimes be helpful. In children less than 3 years, infections and trauma are most frequent. MRI is the imaging modality of choice when osteomyelitis is clinically suspected. Between the ages of 3 and 10 years, transient synovitis of the hip and Legg-Calvé-Perthes disease are main considerations but infection, inflammation and focal bony lesions are also considered. In children over 10 years, slipped capital femoral epiphysis also is considered.     

Do Balance Board Training Programs Reduce the Risk of Ankle Sprains in Athletes?

Introduction Ankle sprains are the most common musculo-skeletal injury that occurs in athletes,particularly in sports that require jumping and landing on one foot such as soccer,and basketball(1-4).These injuries often result in significant time loss from participation,long-term disability,and have a major impact on health care costs and resources(5-8).     

High Intensity Interval Training:New Insights

KEY POINTS ·High-intensity interval training(HIT)is characterized by repeated sessions of relatively brief，intermittent exercise.often performed with an“a11 out”effort or at an intensity close to that which elicits peak oxygen uptake(i.e.，≥90%of VO2 peak).     

Developmental validation of the PowerPlex(®) ESI 16 and PowerPlex(®) ESI 17 Systems: STR multiplexes for the new European standard

In response to the ENFSI and EDNAP groups’ call for new STR multiplexes for Europe, Promega^® developed a suite of four new DNA profiling kits. This paper describes the developmental validation study performed on the PowerPlex^® ESI 16 (European Standard Investigator 16) and the PowerPlex^® ESI 17 Systems. The PowerPlex^® ESI 16 System combines the 11 loci compatible with the UK National DNA Database^®, contained within the AmpFlSTR^® SGM Plus^® PCR Amplification Kit, with five additional loci: D2S441, D10S1248, D22S1045, D1S1656 and D12S391. The multiplex was designed to reduce the amplicon size of the loci found in the AmpFlSTR^® SGM Plus^® kit. This design facilitates increased robustness and amplification success for the loci used in the national DNA databases created in many countries, when analyzing degraded DNA samples. The PowerPlex^® ESI 17 System amplifies the same loci as the PowerPlex^® ESI 16 System, but with the addition of a primer pair for the SE33 locus. Tests were designed to address the developmental validation guidelines issued by the Scientific Working Group on DNA Analysis Methods (SWGDAM), and those of the DNA Advisory Board (DAB). Samples processed include DNA mixtures, PCR reactions spiked with inhibitors, a sensitivity series, and 306 United Kingdom donor samples to determine concordance with data generated with the AmpFlSTR^® SGM Plus^® kit. Allele frequencies from 242 white Caucasian samples collected in the United Kingdom are also presented. The PowerPlex^® ESI 16 and ESI 17 Systems are robust and sensitive tools, suitable for the analysis of forensic DNA samples. Full profiles were routinely observed with 62.5 pg of a fully heterozygous single source DNA template. This high level of sensitivity was found to impact on mixture analyses, where 54–86% of unique minor contributor alleles were routinely observed in a 1:19 mixture ratio. Improved sensitivity combined with the robustness afforded by smaller amplicons has substantially improved the quantity of data obtained from degraded samples, and the improved chemistry confers exceptional tolerance to high levels of laboratory prepared inhibitors.